Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer

Trial Profile

Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 18 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top